91 related articles for article (PubMed ID: 27308523)
21. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation.
Ono R; Kumagai H; Nakajima H; Hishiya A; Taki T; Horikawa K; Takatsu K; Satoh T; Hayashi Y; Kitamura T; Nosaka T
Leukemia; 2009 Dec; 23(12):2197-209. PubMed ID: 19710696
[TBL] [Abstract][Full Text] [Related]
22. Disease-relevant signalling-pathways in head and neck cancer: Taspase1's proteolytic activity fine-tunes TFIIA function.
Gribko A; Hahlbrock A; Strieth S; Becker S; Hagemann J; Deichelbohrer M; Hildebrandt A; Habtemichael N; Wünsch D
Sci Rep; 2017 Nov; 7(1):14937. PubMed ID: 29097782
[TBL] [Abstract][Full Text] [Related]
23. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.
Horiguchi K; Yamada M; Satoh T; Hashimoto K; Hirato J; Tosaka M; Yamada S; Mori M
Clin Cancer Res; 2009 Apr; 15(8):2620-9. PubMed ID: 19318494
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
[TBL] [Abstract][Full Text] [Related]
26. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
[TBL] [Abstract][Full Text] [Related]
27. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
28. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
[TBL] [Abstract][Full Text] [Related]
29. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.
Kühn MW; Armstrong SA
Cancer Cell; 2015 Apr; 27(4):431-3. PubMed ID: 25873167
[TBL] [Abstract][Full Text] [Related]
30. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
31. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.
Xu X; Schneider B
Cell Oncol (Dordr); 2019 Apr; 42(2):117-130. PubMed ID: 30446944
[TBL] [Abstract][Full Text] [Related]
33. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.
Milne TA; Hughes CM; Lloyd R; Yang Z; Rozenblatt-Rosen O; Dou Y; Schnepp RW; Krankel C; Livolsi VA; Gibbs D; Hua X; Roeder RG; Meyerson M; Hess JL
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):749-54. PubMed ID: 15640349
[TBL] [Abstract][Full Text] [Related]
34. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L
Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619
[TBL] [Abstract][Full Text] [Related]
35. CDK9: a signaling hub for transcriptional control.
Bacon CW; D'Orso I
Transcription; 2019 Apr; 10(2):57-75. PubMed ID: 30227759
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional activation by MLL fusion proteins in leukemogenesis.
Yokoyama A
Exp Hematol; 2017 Feb; 46():21-30. PubMed ID: 27865805
[TBL] [Abstract][Full Text] [Related]
37. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.
Ng MH; Ng RK; Kong CT; Jin DY; Chan LC
Exp Hematol; 2010 Jun; 38(6):481-8. PubMed ID: 20362031
[TBL] [Abstract][Full Text] [Related]
38. Structure of AF3p21, a new member of mixed lineage leukemia (MLL) fusion partner proteins-implication for MLL-induced leukemogenesis.
Sano K
Leuk Lymphoma; 2001 Aug; 42(4):595-602. PubMed ID: 11697487
[TBL] [Abstract][Full Text] [Related]
39. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.
Bach C; Mueller D; Buhl S; Garcia-Cuellar MP; Slany RK
Oncogene; 2009 Feb; 28(6):815-23. PubMed ID: 19060922
[TBL] [Abstract][Full Text] [Related]
40. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.
Takeda S; Chen DY; Westergard TD; Fisher JK; Rubens JA; Sasagawa S; Kan JT; Korsmeyer SJ; Cheng EH; Hsieh JJ
Genes Dev; 2006 Sep; 20(17):2397-409. PubMed ID: 16951254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]